While TNF inhibition has demonstrated success in treating autoimmune diseases, such as rheumatoid arthritis or psoriasis, patients undergoing anti-TNF therapy for these indications are at risk for developing demyelinating CNS lesions, indicating a disease-specific effect42,77. This evidence concerns the gene TNF and psoriasis.